Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
4,646 total articles
AAR CORP director Billy Nolen sold 1,562 shares on March 26, 2026, for $173,384 at a weighted average price between $111.0000 and $111.0100. The company recently reported third-quarter fiscal 2026 results that outperformed expectations, prompting multiple firms to raise price targets and maintain or reaffirm Buy ratings.
Jorey Chernett, a 10% owner of Oncology Institute, Inc. (NASDAQ:TOI), acquired 50,000 shares on March 26, 2026, in a series of purchases priced between $3.11 and $3.19, totaling $157,500 at an average of $3.15. The transaction raises Chernett's direct holding to 10,451,929 shares. The buy arrives after the company reported fourth-quarter 2025 resul…
Jorey Chernett, who holds roughly a ten percent ownership stake in Neuronetics, Inc. (STIM), acquired an additional 150,000 shares of the company's common stock across two transactions on March 25-26, 2026, for a combined cost of $211,000. The purchases occurred as the stock traded near $1.45, close to its 52-week low, and follow a quarter that pro…
Charles D. Lake II, Aflac director and chairman of ALIJ, sold 5,000 shares of Aflac common stock on March 25, 2026, for $536,365. The transaction leaves Lake with 57,237 shares directly and 1,327 shares indirectly through a 401(k). The stock trades at $108.21, with a market capitalization of $55.75 billion. Recent company results were mixed, with a…
Yorktown Energy Partners XI, L.P., a holder of roughly 10% of Ramaco Resources, Inc., sold 9,330 shares of the company's Class B common stock across March 24-26, 2026, collecting $104,792. The sales reduced the investor's exposure but left it with a substantial holding of 1,243,197 Class B shares. The transactions occurred while Ramaco's stock trad…
Yorktown IX Associates LLC, a roughly 10% holder of Ramaco Resources, sold 9,207 shares of Class B common stock across three transactions from March 24-26, 2026, generating proceeds of $103,411. The trades were executed at prices between $10.7833 and $11.5756 per share. After the sales, Yorktown IX directly holds 1,226,642 shares. Ramaco’s stock tr…
Director Bryan H. Lawrence sold $5,823,990 of Ramaco Resources Inc. (METC) stock across March 24-26, 2026, disposing of both Class A and Class B shares at prices between $10.7833 and $14.0605. The company is trading at $13.97, materially below its 52-week high but up over the past year. Recent corporate developments include Q4 2025 results showing …
Yorktown Energy Partners IX, L.P., a 10% holder of Ramaco Resources, Inc. (NASDAQ: METC), sold 9,207 Class B shares over three days between March 24 and March 26, 2026, for a combined $103,411. The transactions reduced Yorktown's direct stake to 1,226,642 shares. Ramaco recently reported Q4 2025 results showing improved financial footing despite an…
Yorktown XI Associates LLC, a roughly 10% holder of Ramaco Resources, Inc. (NASDAQ: METC), disposed of 9,330 Class B shares in three transactions between March 24 and March 26, 2026, for about $104,792. The sales leave the entity with an indirect holding of 1,243,197 Class B shares. The transactions occur while METC trades well below its 52-week hi…
Jessica Flores, Executive Vice President and Chief Accounting Officer of Sabra Health Care REIT (NASDAQ: SBRA), sold 15,231 shares of the company's common stock on March 25, 2026 for $302,487. The transaction took place at a weighted average price of $19.86 per share, with individual sale prices ranging from $19.85 to $19.89. Following the sale, Fl…
Control Empresarial de Capitales S.A. de C.V., a roughly 10% holder of PBF Energy Inc., sold 1,157,200 Class A common shares on March 24 and 25, 2026, raising $57,243,673. The disposals were executed in several tranches at prices between $48.5276 and $50.0871 per share. The sales come while PBF shares trade close to their 52-week high, following a …
BFI Co., LLC, a 10% holder of Phibro Animal Health Corp, sold 15,500 Class A shares from March 24 to March 26, 2026, generating roughly $1.16 million under a pre-arranged 10b5-1 plan. The sales occurred as PAHC shares have climbed 161% over the past year and trade close to a 52-week high; the company recently reported fiscal Q2 2026 results that be…
Slide Insurance Holdings Inc. CEO Bruce Lucas sold 237,536 shares of common stock in two transactions on March 24 and March 26, 2026, generating proceeds of $4.28 million. The trades were executed through IIM Holdings II, LLC. The disclosures come amid a recent 10% weekly increase in SLDE shares, robust fourth-quarter results and a newly authorized…
Slide Insurance Holdings President and COO Lucas Shannon sold 23,493 shares on March 24 and March 26, 2026, realizing about $423,581. The transactions were executed through Securus Risk Management, LLC. The stock had advanced over 10% in the prior week. Separately, Slide Insurance reported stronger-than-expected fourth-quarter results, completed a …
Olivia Nottebohm, chief operating officer at Box, Inc., sold 5,942 shares of Class A common stock on March 25, 2026, under a Rule 10b5-1 plan. The trade, executed at $24.10 per share, totaled $143,202. The transaction follows a six-month, 26% decline in Box shares, which were trading at $23.82 at the time of reporting. Separately, Box reported quar…
F5, Inc. President, CEO and Director Francois Locoh-Donou sold 3,334 shares of common stock on March 25, 2026, for $300 per share, generating proceeds of $1,000,200. The transaction was executed under a Rule 10b5-1 trading plan established on December 3, 2025. F5 reported stronger-than-expected first-quarter 2026 results and unveiled multiple produ…
F5, Inc. Chief Financial Officer Werner Edward Cooper sold 1,000 shares on March 25, 2026, for $300.00 per share, totaling $300,000. The transaction was carried out under a prearranged Rule 10b5-1 plan dated December 3, 2025. Following the sale, Cooper directly holds 4,305 shares. The sale occurred near the stock's prevailing price and after a quar…
Village Farms International President of Canadian Cannabis Orville Bovenschen disposed of 50,000 common shares on March 25, 2026, in multiple open-market trades totaling $144,500. The sale was reported on a Form 4 filing. The transaction comes amid a fourth-quarter 2025 earnings miss and a market price that trades below analyst fair value ranges.
Peter Altman, President and CEO of BioCardia, Inc. (NASDAQ: BCDA), purchased 900 shares across two days in late March 2026 for a combined $1,110. The trades slightly raise his direct stake to 274,766 shares while the company reports modestly wider expenses and a net loss as it advances its CardiAMP therapy and engages with regulators.
Anthony Mancini, Chief Global Commercialization Officer at Revolution Medicines, sold 26,552 shares on March 25, 2026, in transactions totaling roughly $3.5 million and exercised options to acquire an additional 37,450 shares. The stock has posted strong gains over recent periods but is flagged by InvestingPro as overvalued versus its Fair Value. R…
Acadia Pharmaceuticals Chief Financial Officer Mark C. Schneyer sold 7,385 shares between March 25 and March 26, 2026, to cover withholding taxes tied to vested restricted stock units. The transactions generated approximately $159,135 in proceeds. Schneyer also received 14,316 shares on March 24 and 25 upon RSU vesting. The company recently reporte…
James Kihara, Acadia Pharmaceuticals' Principal Accounting Officer, disposed of 1,942 shares valued at $41,895 between March 25 and March 26, 2026. The sales, undertaken to satisfy withholding tax obligations, came immediately after restricted stock units vested and converted into 3,769 shares on March 24 and 25. The stock trades at $21.47, with a …
Andrew Bialecki, Co-CEO of Klaviyo Inc. (KVYO), sold 200,000 Series A shares on March 24, 2026, for $3.634 million under a pre-established Rule 10b5-1 trading plan. The transaction coincided with a conversion of 200,000 Series B shares into Series A and follows a roughly 40% drop in Klaviyo's stock over six months. The company has also announced a …
Acadia Pharmaceuticals CEO Owen Adams Catherine sold 11,641 shares on March 25, 2026, at $21.47 per share, generating approximately $249,932. The sale followed the conversion of 23,509 restricted stock units to common shares on March 24, 2026. Acadia's shares are down about 20% year-to-date but up roughly 25% over the past year. Additional corporat…
Jennifer J. Rhodes, Executive Vice President, Chief Legal Officer and Secretary of Acadia Pharmaceuticals, sold 3,844 shares of the company's common stock on March 25, 2026, raising $82,530. The sale followed an exercise of options for 7,515 shares at no cost on March 24, 2026. Acadia is trading below its InvestingPro Fair Value even as the company…
